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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a devastating disease whose complex pathology has been
associated with a strong genetic component in the context of both familial and sporadic disease. Herein, we
adopted a next-generation sequencing approach to Greek patients suffering from sporadic ALS (together with their
healthy counterparts) in order to explore further the genetic basis of sporadic ALS (sALS).
Results: Whole-genome sequencing analysis of Greek sALS patients revealed a positive association between FTO
and TBC1D1 gene variants and sALS. Further, linkage disequilibrium analyses were suggestive of a specific disease-
associated haplotype for FTO gene variants. Genotyping for these variants was performed in Greek, Sardinian, and
Turkish sALS patients. A lack of association between FTO and TBC1D1 variants and sALS in patients of Sardinian and
Turkish descent may suggest a founder effect in the Greek population. FTO was found to be highly expressed in
motor neurons, while in silico analyses predicted an impact on FTO and TBC1D1 mRNA splicing for the genomic
variants in question.
Conclusions: To our knowledge, this is the first study to present a possible association between FTO gene variants
and the genetic etiology of sALS. In addition, the next-generation sequencing-based genomics approach coupled
with the two-step validation strategy described herein has the potential to be applied to other types of human
complex genetic disorders in order to identify variants of clinical significance.
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Introduction
Amyotrophic lateral sclerosis (ALS), also known as Lou
Gehrig’s disease, is a neurodegenerative disorder that af-
fects the upper and lower motor neurons in the motor
cortex, brain stem, and spinal cord [20]. ALS was first
described in the mid-1800s as a rapidly progressing
motor neuron disease, with phenotypes of varying sever-
ity. Affected patients present muscle weakness, atrophy,
and a general progressive paralysis. Eventually, most
develop respiratory failure which leads to death on aver-
age 3 to 5 years after the onset of symptoms [45]. As
yet, there is no effective treatment or pre-symptomatic
diagnostic test for ALS [11].
Approximately 90–95% of ALS patients suffer from
a sporadic form of ALS (sALS), which has both an
environmental etiology and a likely strong genetic
component [23]. The remaining 5–10% of ALS pa-
tients exhibit a clear genetic etiology for the disease,
also known as familial ALS (fALS). Genomic variants
in the SOD1 gene have been shown to lead to fALS,
with an autosomal dominant mode of inheritance. To
date, more than 170 different SOD1 genomic variants
have been reported, affecting ~ 13% of fALS and ~ 1%
of sALS patients [40]. Furthermore, variants in other
genomic loci, such as FUS [27], TARDBP [25], and
more recently C9orf72 [36], have also been implicated
in fALS. In the case of C9orf72, a non-coding
GGGGCC expansion appears to have a very strong
association with both fALS and sALS, with an overall
prevalence of 40 and 5–20% in fALS and sALS
patients, respectively [39].
The etiology of sALS is quite complex. A variety of dif-
ferent factors, including age, overall lifestyle, occupation,
and/or exposure to xenobiotics, appear to influence the
risk of developing sALS, but no specific chemical or
toxin has been identified as a direct cause of ALS [44].
In addition to environmental factors, sALS also has a
substantial genetic component. Genome-wide associ-
ation studies have so far identified over 100 genomic loci
that could yet prove to be linked to ALS disease predis-
position with low-to-medium penetrance, supporting the
notion of pronounced heritability for ALS [reviewed in
[28]]. From these genomic loci, SQSTM1 [19], UBQLN2
[14], VCP [12], ANG [29], PRPH [38], DCTN1, TAF15,
and SETX [10] appear to be more frequently mutated in
sALS than in fALS, with an overall prevalence of be-
tween 4 and < 1%; these findings have been confirmed in
several studies/cohorts as well as in functional and
animal studies. Furthermore, the co-occurrence of gen-
omic variants in addition to the presence of de novo
pathogenic variants in sALS brings the estimate of over-
all heritability for ALS to as high as 60% [3, 4]. The
identification of the entire lexicon of underlying genetic
defect(s) in both fALS and sALS patients and their
families would greatly improve disease diagnosis and po-
tentially disease management.
There is little knowledge of the genetic basis of ALS in
fALS and sALS patients of Greek origin. Although the
incidence of ALS in Greek patients is comparable to
other European populations (~ 1–2 per 100,000), only a
single study has so far been performed, highlighting a ra-
ther high prevalence of the C9orf72 GGGGCC repeat
expansion in Greek ALS patients [35]. Here, we report a
novel genomic locus, FTO, that appears to be associated
with sALS. Genomic data comparison with sALS pa-
tients of Greek, Sardinian, and Turkish descent strongly
suggest that this association may represent a founder ef-
fect that is specific to the Greek population.
Materials and methods
Case selection
Adopting a three-step strategy to determining data reli-
ability, case selection criteria spanned all three patient
cohorts studied herein (Fig. 1): (i) whole-genome se-
quencing analysis in sALS Greek patients (n = 6) and
their healthy counterparts (n = 5), (ii) SNP genotyping
(selected variants of interest) in sALS Greek patients
(n = 28) and their healthy counterparts (n = 50), and
(iii) SNP genotyping (selected variants of interest) in
sALS patients of Greek (n = 114), Sardinian (n = 114),
and Turkish (n = 148) origin and their healthy coun-
terparts (n = 39, n = 87, n = 74, respectively). Patients
were independently evaluated by at least two senior
neurologists and diagnosed on the basis of revised El
Escorial criteria [9]. Patients with definite, probable,
probable laboratory supported, or possible ALS were
included in the study. Healthy individuals were re-
cruited after excluding the occurrence of common
neurological disorders.
Whole-genome sequencing and bioinformatics analyses
Genomic DNA isolation was performed either from
peripheral blood using the QIAamp Blood Midi Kit
(Qiagen GmbH, Hilden, Germany) or by means of the
phenol-chloroform extraction method as previously de-
scribed with minor modifications or saliva as previously
described [1]. Whole-genome sequencing was performed
using Complete Genomics’ (CA, USA) DNA nanoarray
platform [18]. DNA sequencing coverage was ×110.
Only high-quality call variants were included in the
downstream analysis (> 93%). Genomes were aligned
with the hg19 reference genome. Next-generation
sequencing data (Complete Genomics Inc., CA) were
analyzed using Ingenuity Variant Analysis version 3.1.2
(Ingenuity® Systems, www.ingenuity.com). This is well-
established software that identifies associations between
phenotypes, defined by the user in terms of the classifi-
cation of the tested individuals, and variants in the
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sequenced genome. Upon classification by phenotype
(sALS vs. healthy individuals), a number of variants were
listed; the output was filtered into smaller variant lists of
(i) those found only in sALS patients (n = 174 single
nucleotide polymorphisms (SNPs)), (ii) those not
previously annotated or annotated only once, (iii) those
with matching Human Gene Mutation Database
(HGMD) entries, and (iv) whole-exome findings. All var-
iants were filtered according to the analysis required,
using custom scripts and Complete Genomics Analysis
Tools (CGA™ Tools).
Linkage disequilibrium and in silico analyses
Pair-wise linkage disequilibrium (LD) calculations
were based on phase genotype data (SNAP v2.2) [24],
utilizing the HapMap Phase II + III (release 28) [6]
and the 1000 Genomes Project (http://www.1000geno-
mes.org) dataset for Caucasians (CEU). Findings were
visualized on HaploView 4.2 and by using the LDma-
trix module on the LDlink web tool [30]. Τo further
investigate the role of the selected FTO and TBC1D1
variants, we explored their effect on splicing motifs
(including the “accept” and “donor” splice sites), the
branch point, and auxiliary sequences that enhance
(exonic splicing enhancers, ESE) or repress (exonic
splicing silencers, ESS) splicing. To this end, in silico
prediction was performed, using Human Splicing
Finder (http://www.umd.be/HSF3/). This is a system
that has rapidly become an international standard, as
it combines 12 different algorithms [15]. Intronic
variants, if “significant,” are often located within gene
regions that are characterized by a reduced level of
genetic variation. Conserved elements were therefore
explored using Variant Effect Predictor [34].
Downstream molecular genetic analysis
The first patient cohort served as our discovery dataset,
while the second and third patient cohorts constituted
our training datasets (Fig. 1). For this process, selected
variants were subsequently validated in sALS Greek pa-
tients (n = 28) and their healthy counterparts (n = 50)
(Fig. 1, Tables 1 and 2 and Additional file 1). PCR ampli-
fication was carried out according to the KAPA2G Fast
HotStart protocol (KAPABIOSYSTEMS, MA, USA); de-
tailed information regarding SNP amplification condi-
tions is available upon request. For FTO rs2892469
(C>T) and rs1861869 (G>C), a PCR-based conventional
Sanger resequencing approach was employed. Capillary
electrophoresis was performed on an ABI Prism 3130xl
DNA Analyzer (Applied Biosystems). For FTO
rs17217144 (C>T) and rs7186521 (A>G) as well as
TBC1D1 rs6850200 (C>A), allele-specific PCR assays
were developed (two alternative reverse primers hybrid-
izing exclusively either to the wild-type or the mutant al-
lele). Sanger sequencing was also employed to validate
the allele-specific PCR method.
Table 1 Selected FTO and TBC1D1 gene variants of prime interest
Gene SNPs Alleles MAF-all MAF-EUR Variant type
FTO rs2892469 C>T 0.31 (T) 0.49 (T)
Intronic
rs1861869 C>G 0.38 (G) 0.54 (G)
rs17217144 C>T 0.31 (T) 0.49 (T)
rs7186521 A>G 0.37 (G) 0.49 (G)
TBC1D1 rs6850200 C>A 0.41 (A) 0.37 (A)
Fig. 1 Our three-step strategy towards data reliability. Our three-step strategy involved three patient cohorts: (i) whole-genome sequencing ana-
lysis in sALS Greek patients (n = 6) and their healthy counterparts (n = 5), (ii) SNP genotyping (selected variants of interest) in sALS Greek patients
(n = 28) and their healthy counterparts (n = 50), and (iii) SNP genotyping (selected variants of interest) in sALS patients of Greek (n = 114), Sardinian
(n = 114), and Turkish (n = 148) origin and their healthy counterparts (n = 39, 87, 74, respectively). The first patient cohort served as the discovery
dataset, while the second and third patient cohorts were the training datasets
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Sizing PCR across the C9orf72 hexanucleotide repeats
was performed using previously published primers [13]
using repeat-primed PCR [32, 39]. Fragment length
analysis was performed with the ABI 3500 genetic
analyzer (Applied Biosystems, Foster City, Calif., USA)
and analyzed using ABI GeneMapper v4.1 (Applied
Biosystems).
qRT-PCR expression analysis for the FTO and TBC1D1 genes
The relative expression levels of FTO and TBC1D1 were
determined using human-specific primers in a range of
various human cell types; fibroblasts, embryonic stem
cells (ESCs), astrocytes, neural PAX6+ progenitors, stem
cell-derived purified motor neurons at three different
stages of development (Hb9::GFP on days 0, 16, and 30),
and stem cell-derived cortical neurons (NKX21 on days
45 and 50). Human brain and spinal cord RNA served
as controls. Cell pellets were resuspended in Trizol
Reagent (Life Technologies), and RNA was isolated fol-
lowing the manufacturer’s protocol. 0.5 to 1 μg of RNA
was treated with DNase I (Invitrogen) and subsequently
used for the generation of cDNA using iSCRIPT Reverse
Transcription Supermix (Bio-Rad). RT-PCR was per-
formed using SYBR green on the CFX system (Bio-Rad).
All assays were performed in triplicate. The averaged
cycle of threshold (Ct) value of the two housekeeping
genes (ACTIN/GAPDH) was subtracted from the Ct
value of the gene of interest to obtain the ΔCt. Relative
gene expression was determined as 2−ΔCt (ΔΔCt) and
expressed relative to undifferentiated human embryonic
stem cells (hESCs).
Statistical analysis
Deviations from Hardy-Weinberg equilibrium were
tested for using Pearson’s goodness-of-fit chi-square (de-
grees of freedom = 1), log likelihood ratio chi-square
(degrees of freedom = 1), and Fisher’s Exact tests. De
Finetti diagrams were also constructed [41]. Focusing on
case-control (healthy individuals) phenotypes, we tested
the null hypothesis of no association between rows and
columns of the 2 × 3 matrix that contains the counts of
the three genotypes (the two homozygotes and the het-
erozygote) among cases and controls. Genotype and
allele frequencies were evaluated using Fisher’s exact
test. We also performed the Armitage test (Monte Carlo
method; it obtains results that are closer to those of an
exact test, since the classical Cochran-Armitage trend
test is based on approximation) [5]. All tests were per-
formed as two-tailed, and differences were considered to
be statistically significant when P < 0.05. Further calcula-
tions using contingency tables (chi-square test) were
performed to explore data stratification, considering (i)
the age of onset (below or above 50 years old), (ii) El Es-
corial criteria, and (iii) spinal or bulbar ALS onset.
Results
Whole-genome sequencing analysis of Greek sALS
patients reveals a positive association with FTO and
TBC1D1 variants
Our next-generation sequencing-based genomics ap-
proach yielded a total of 174 SNPs that were found only
in the sALS patients studied; these were variously inter-
genic (n = 144), intronic (n = 23), and/or were present in
upstream (n = 2), downstream (n = 1), and 3′UTR (n = 2)
regions or non-coding RNAs (n = 2). Next, genes were
clustered by metabolic or disease network and the most
prominent ones are shown in Table 3. Our data analysis
revealed three genomic variants of prime interest: FTO
rs2892469 (C>T) and rs1861869 (G>C) and TBC1D1
rs6850200 (C>A). Findings were further explored in
Greek sALS patients and their healthy counterparts (sec-
ond patient cohort). FTO intronic variants, rs2892469
(C>T) and rs1861869 (G>C), reached statistical signifi-
cance (p = 0.005 and p = 0.003, respectively). For
TBC1D1 rs6850200 (C>A), a strong association also be-
came evident (p value of 0.017). Data are summarized in
Tables 1 and 2 and Additional file 1.
In addition, a C9orf72 hexanucleotide expansion was
identified in 1 of 28 patients with sALS (3.5%;
Additional file 1: Table S4). This female patient was di-
agnosed with unequivocal ALS but was devoid of a
positive family history for ALS.
Linkage disequilibrium analyses suggest a haplotype of
FTO gene variants
Our findings support a disease-associated haplotype
constituting FTO rs2892469 (C>T), rs1861869 (G>C),
rs17217144 (C>T), and rs7186521 (A>G) (Fig. 2). SNAP
analysis (HapMap datasets) was in agreement with the
HaploView v4.2 analysis (our Greek cohort). The same
result was produced for the LDmatrix module on the
LDlink web tool. rs2892469 and rs1861869 are in perfect
linkage disequilibrium (LD) (D′ = 1, LOD = 23.66, r2 =
0.884), while rs17217144 and rs7186521 exhibit a strong
LD (D′ = 0.882, LOD = 10.1, r2 = 0.738). Block1 is based
on confidence intervals, i.e., it was created due to 95% of
informative comparisons being in “strong LD.” Such
findings serve as a paradigm as to how information tech-
nology tools coupled to experimental data may empower
discovery.
In silico analyses suggest that FTO and TBC1D1 variants
affect splicing
TBC1D1 rs6850200 (C>A) and FTO rs2892469 (C>T)
were predicted to create a splicing enhancer site which
would potentially alter splicing. In the case of FTO
rs1861869 (G>C), a putative exonic splicing silencer site
is disrupted, while FTO rs7186521 (A>G) appears to
have created a new donor splice site. No impact on
Mitropoulos et al. Human Genomics  (2017) 11:30 Page 5 of 10
splicing was predicted for FTO rs17217144 (C>T). Using
Variant Effect Predictor, PhyloP, and PhastCons data
showed that the selected FTO variants are evolutionarily
conserved.
Replication analyses
Replication analyses were carried out in sALS patients of
Greek origin (to ensure data reliability) and Sardinian
and Turkish descent (to account for population
differences (third patient cohort)). We found that four
FTO intronic variants, rs2892469 (C>T) and rs1861869
(G>C), rs17217144 (C>T), and rs7186521 (A>G),
reached statistical significance (p = 0.033, p = 0.07, p =
0.002, and p < 0.001, respectively), when Greek sALS pa-
tients were compared to their healthy counterparts. For
TBC1D1 rs6850200 (C>A), the aforementioned strong
association (p value of 0.017) no longer held upon repli-
cation in Greek sALS patients (p value of 0.723). Data
stratification based upon (i) the age of onset (below or
above 50 years old), (ii) El Escorial criteria, and (iii)
spinal or bulbar ALS onset did not alter our findings. It
should be noted that all FTO and TBC1D1 variants
failed to reach statistical significance, even when strati-
fied for SOD1, when Sardinian and Turkish sALS pa-
tients were considered. Data are summarized in Tables 1
and 2. The lack of association of these variants with
sALS in patients of Sardinian and Turkish descent may
suggest a founder effect in the Greek population.
FTO is highly expressed in motor neurons
To begin defining genotype-to-phenotype associations for
FTO, TBC1D1, and ALS, we determined the relative
mRNA levels for both genes across several human cell
types. We specifically analyzed fibroblasts, undifferenti-
ated embryonic stem cells (ESCs), astrocytes, neural PAX6
+ progenitors, and stem cell-derived spinal cord motor
neurons (MNs) and cortical neurons (CNs). We used the
HUES3-Hb9::GFP cell line, which contains a GFP reporter
under the control of the MN-specific Hb9 enhancer [17]
to differentiate and FACS-purify MNs as described previ-
ously [26], on three different stages of development (days
0, 16, and 30). We also used the NKX2.1::GFP ESC line to
differentiate and FACS-purify cortical neurons as de-
scribed previously [33] on three different stages of devel-
opment (days 45 and 50). Our qRT-PCR data show that
FTO is relatively neural specific and notably is most highly
expressed in motor neurons (Fig. 3). TBC1D1 seems to be
rather ubiquitously expressed.
Discussion
sALS is polygenic with a complex interplay with envir-
onmental and other factors. Previous studies have pro-
posed genetic associations of a variety of genes with the
etiology of sALS. In this article, we adopted a three-step
approach to delineate the association of genomic vari-
ants with sALS in patients of Greek origin.
Using a next-generation sequencing-based genomics
approach, we identified 174 variants that were only
present in the initial sALS patients studied. We opted to
focus on the FTO rs2892469 (C>T) and rs1861869
(G>C) and TBC1D1 rs6850200 (C>A) variants, based on
pathway analysis. Our replication analyses confirmed
that the FTO but not the TBC1D1 genomic variants
Table 3 Gene clustering per metabolic or disease network
using Ingenuity Pathway Analysis (IPA) to assist decision-making
Disease or metabolic network Genes p value
Neural cell proliferation ISL1, FTO, ADCYAP1,
ΟΤΡ, SPP1
6.02 × 10–5
Motor neuron proliferation ISL1, FTO 9.53 × 10–5
Motor neuron dysfunction ISL1, WNT4 1.28 × 10–3
Development of neuromuscular
junction
PDZRN3 1.65 × 10–3
Branching of sensory neurons PRKG1 1.65 × 10–3
ALS FUS 1.65 × 10–3
Development of P and M cells
of visual nervous system
ΟΤΡ 1.65 × 10–3
Growth of cerebellar cortex,
regulation of upper cervical
ganglia
ADCYAP1 1.65 × 10–3
Cranial nerve development ISL1, ERBB4 1.9 × 10–3
Brain development ADCYAP1, ERBB4,
FTO, ΟΤΡ, PRKG1
2.56 × 10–3
Development of specific nerves
of the hand, area of dendritic
trees
ISL1 3.3 × 10–3
Movement of the cranial neural
crest, participation in the
formation of the central nervous
system, astrocyte attachment
ERBB4 3.3 × 10–3
Neural cell number ADCYAP1, ERBB4,
WNT4, SPP1
3.75 × 10–3
Nervous system morphology ERBB4, FTO, WNT4,
SPP1, YES1, ISL1
6.33 × 10–3
Oligodendrocyte development,
excitatory synapse formation
ERBB4 6.6 × 10–3
Central nervous system
development, dendritic cell
development
ERBB4, ADCYAP1 7.4 × 10–3
Motor neuron sprouting FTO 9.88 × 10–3
v3 spinal cord motor neuron
sprouting
FTO 9.88 × 10–3
Midbrain size FTO 9.88 × 10–3
Neuronal withdrawal WNT4 1.32 × 10–2
Brain morphology ERBB4, FTO, SPP1,
YES1
1.35 × 10–2
Neuronal branching ERBB4, ADCYAP1,
PRKG1
1.58 × 10–2
DNA repair APTX, FTO, FUS 1.65 × 10–2
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maintained their statistical significance as far as their as-
sociation with sALS was concerned. Data stratification
considering (i) the age of onset (below or above 50 years
old), (ii) El Escorial criteria, and (iii) spinal or bulbar
ALS onset did not affect our findings (not shown).
We subsequently attempted to explore whether the
FTO gene variants identified as being associated with
sALS in Greek patients might also be associated with
sALS in patients of Turkish and Sardinian descent.
However, genetic analysis of all FTO and TBC1D1 vari-
ants failed to reach statistical significance, even when
stratified for SOD1, when Sardinian and Turkish sALS
patients were considered. This may be due to a founder
effect in the Greek population.
In order to explore the functional significance of our
findings, we measured the FTO and TBC1D1 gene ex-
pression levels in several human cell types, namely fibro-
blasts, embryonic stem cells (ESCs), astrocytes, neural
PAX6+ progenitors, stem cell-derived purified motor
neurons at three different stages of development
(Hb9::GFP on days 0, 16, and 30), and stem cell-derived
cortical neurons (NKX21 on days 45 and 50). Our qRT-
PCR data demonstrated that FTO gene expression is
relatively neuron-specific and notably is highly expressed
in motor neurons (Fig. 3). By contrast, TBC1D1 would
appear to be rather ubiquitously expressed.
Interestingly, long distance interactions have been re-
ported for the FTO intronic region: (i) obesity-associated
non-coding sequences within FTO interact with the pro-
moter regions of IRX3 and FTO in human, mouse, and
zebrafish, and (ii) obesity-associated FTO gene variants
influence IRX3 expression in the human brain. The lat-
ter gene was associated with body mass, as IRX3-defi-
cient mice displayed a decrease in their body weight by
25–30% [42]. Nutritional surveillance of ALS patients
has been well established to be of fundamental import-
ance, both in bulbar and spinal onset patients, and
nutritional status is a prognostic factor for survival in
ALS patients [16]. Jawaid et al. [22] reported that a de-
crease in body mass index is associated with faster pro-
gression of motor symptoms and shorter survival in ALS
patients. Moreover, an LD block of 49 kb in the first
intron of FTO contains numerous highly conserved non-
coding elements (HCNEs) and lies within an extended
region of conserved synteny involving the IRX3/5/6
cluster, the closest gene of which is the transcription
factor-encoding IRX3 [37]. IRX3 is a member of the Iro-
quois homeobox gene family and plays a role in the early
stages of neural development [7].
We also identified an example of C9orf72 hexanucleo-
tide expansion in 1 of 28 patients with sALS (3.5%;
Additional file 1: Table S4). This female patient, harbor-
ing this expansion, was diagnosed with unequivocal ALS
but was lacked a positive family history of ALS. This
massive hexanucleotide repeat expansion mutation in
C9orf72, which has been linked to fALS, sALS, and fron-
totemporal dementia, has a single founder who is
thought to have originated approximately 6300 years ago
in Europe [31, 43]. Our findings differ somewhat from
those reported by Mok and coworkers [35], the only
study to date in fALS and sALS patients of Greek
descent, in which 11 of 136 sALS patients (8.2%) were
Fig. 2 Linkage disequilibrium and haplotype block analysis for FTO rs2892469, rs1861869, rs17217144, and rs7186521. Data suggest a haplotype
for the FTO genomic variants studied herein. SNAP analysis refers to HapMap datasets, while the HaploView v4.2 analysis corresponds to our
Greek cohort. The HaploView 4.2 color scheme denotes the following: white (D′ < 1, LOD < 2) and red (D′ = 1, LOD ≥ 2). rs2892469 and rs1861869
are in perfect LD (D′ = 1, LOD = 23.66, r2 = 0.884); rs17217144 and rs7186521 exhibit a strong LD (D′ = 0.882, LOD = 10.1, r2 = 0.738). Block1 is based
on confidence intervals, i.e., it was created through 95% of informative comparisons being in “strong LD”
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carriers of the expansion. Such a discrepancy may reflect
inter-individual differences not as far as statistical power
is concerned, but rather related to the patients’ genetic
background, as the aforementioned study examined only
individuals from Athens, whereas we recruited individ-
uals from across the entire Greek mainland (north, cen-
tral, and south Greece). Differential exposure to
environmental factors are known to contribute to an in-
creased risk of ALS; thus, exposure to lead, mercury, sel-
enium, zinc, and copper is known to increase the risk of
ALS [46], while high-risk populations include those who
collect their domestic water from surface water [8],
possibly reflecting an association between the neuro-
toxin b-methylamino-l-alanine (BMAA) produced by
cyanobacteria and the risk of ALS. Al-Chalabi and
Hardiman [4] have proposed a disease model, according
to which ALS is the net result of environmental risks
and time acting on a pre-existing genetic load, followed
by an automatic, self-perpetuating decline until death.
Akimoto et al. [2] reported marked differences in geno-
typing results for GGGGCC-repeat expansions in
C9orf72. Herein, amplicon length analysis and repeat-
primed PCR were combined as a recommended mini-
mum requirement in a research setting [2].
Fig. 3 a, b FTO and TBC1D1 expression levels in a range of various human cell types. FTO and TBC1D1 mRNA levels were determined using
human-specific primers in various cell types; fibroblasts, embryonic stem cells (ESCs), astrocytes, neural PAX6+ progenitors, stem cell-derived
purified motor neurons at three different stages of development (Hb9:GFP on days 0, 16, and 30), and stem cell-derived cortical neurons (NKX21
on days 45 and 50). Human brain and spinal cord RNA served as controls. Normalized RT-qPCR data are expressed as averaged sample replicates.
Error bars represent standard deviations
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Small sample sizes and data variability, plus our ances-
trally diverse patient cohorts, should be taken into ac-
count when interpreting our findings. Yet, our datasets
may assist future efforts of replicating these findings in
independent ALS patient cohorts.
Conclusions
There is no single predominant genetic association
underlying sALS. Instead, sALS may be considered to be
the net result of the complex interplay of environmental
factors and numerous low-risk susceptibility loci. We
propose that under this polygenic model, a large number
of alleles, each conferring a small genotypic risk, com-
bine additively or multiplicatively to confer a range of
susceptibilities in the general population [21, 47].
To our knowledge, this has been the first study to
present a possible association between FTO variants and
the genetic basis of sALS. These findings need to be fur-
ther validated in a larger sALS patient cohort of Greek
origin to overcome the small sample size bias, while a
gene ontology analysis to look at links between FTO and
the other genes known to be associated with ALS could
support the validity of these findings.
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